Objective: Menopause age can affect the risk of developing cardiovascular disease (CVD). The purpose of this study was to investigate the associations of early menopause (menopause occurring before age 45 y) and menopause age with N-terminal pro brain natriuretic peptide (NT-proBNP), a potential risk marker of CVD and heart failure.
arly menopause has been linked to greater cardiovascular disease (CVD) risk 1<3 and has been shown to be associated with a greater incidence of heart failure (HF), 4 coronary artery disease, and stroke. 5 CVD is the leading cause of death in women, 6 and early diagnosis is useful for optimization of care and improvement in therapy. 7 There are currently no biomarkers for identifying women with early menopause who are more prone to developing CVD. Sex hormones could affect natriuretic peptide levels, 8 and the postmenopausal period is defined by hormonal changes such as estrogen deficiency and relative androgen predominance. 9 N-terminal pro brain natriuretic peptide (NT-proBNP) is a biomarker for the diagnosis, prognosis, and management of women with CVD and HF. 7 ,10<12 NT-proBNP can easily be measured in the clinical setting and may be a useful marker for high-risk women with early menopause.
Some factors that affect NT-proBNP, such as age, 13 smoking, 14 ethnicity, 15 and body mass index (BMI), 8, 11, 13, 16, 17 could also affect menopause age. 18<21 Women have greater NT-proBNP levels than men, 8, 13 and menopause, which is a consequence of aging, 22 occurs specifically in women. It is not known if a woman's menopause age is associated with NT-proBNP, after accounting for traditional CVD risk factors. Examination of relationships between menopause age and NT-proBNP could also provide insights into the mechanisms underlying increased CVD risk in early postmenopausal women. We tested the hypothesis that early menopause is independently associated with greater NT-proBNP levels, whereas each 1-year increase in menopause age is independently associated with lower NT-proBNP levels, in the Multi-Ethnic Study of Atherosclerosis (MESA). Because NT-proBNP levels are lower in African Americans than in whites, 15, 16 we also hypothesized that the associations of early menopause and menopause age with NT-proBNP vary according to ethnicity.
METHODS

Study population
MESA is a population-based cohort of 6,814 participants (3,601 women) of white (38%), African-American (28%), Chinese-American (12%), and Hispanic (22%) descent, aged 45 to 84 years (2000) (2001) (2002) , and without clinical CVD before recruitment. MESA's design and objectives have been published. 23 The aim of MESA was to study the characteristics of subclinical CVD and the risk factors that predict progression to clinical disease. The study protocol was approved by institutional review boards at participating sites, and a written informed consent form was obtained from participants. There were 2,949 postmenopausal women at baseline. We excluded 34 women who concurrently reported being perimenopausal and 640 women who did not have serum samples for NT-proBNP measurements, thus obtaining a sample size of 2,275 for our cross-sectional study. The prevalence of early menopause was similar among participants (24.7%) and women excluded from this study (25.1%).
Baseline measurements
Standardized questionnaires were used to collect information on menopause, ethnicity, educational status, cigarette smoking, use of hormone therapy, medications, hypertension, diabetes, and prior oophorectomy. Women were asked if they had experienced Bmenopause[ or Bchange of life[ and asked for the age at which they experienced menopause. Women who reported that they were perimenopausal were asked to provide the date of their last menstrual period and the number of periods they had experienced in the last 12 months. Menopause was defined as the absence of periods for at least 12 months in the absence of pregnancy. Participants were classified as having early menopause if they experienced menopause before age 45 years.
BMI was calculated as weight divided by the square of height (kg/m 2 ). Hypertension was defined as systolic blood pressure of 140 mm Hg or higher, diastolic blood pressure of 90 mm Hg or higher, or use of antihypertensive medication. Fasting plasma glucose and insulin levels were measured by glucose oxidase and radioimmunoassay methods, respectively. 24, 25 Diabetes was defined as a fasting plasma glucose level of 126 mg/dL or higher or use of hypoglycemic medications. 25 Insulin resistance, indicated by homeostasis model assessmentYinsulin resistance, was calculated as follows: fasting glucose (mmol/L) Â fasting insulin (KU/mL) / 22.5. 25 High-density lipoprotein cholesterol was measured via a cholesterol oxidase reaction using fasting samples. 24 Interleukin-6 was measured with an ultrasensitive enzyme-linked immunosorbent assay. 26 Serum creatinine measured by colorimetry was used to determine creatinine-based estimated glomerular filtration rate. 27 Resting 12-lead electrocardiograms (ECGs) were obtained, centrally read, and coded for the presence of left ventricular hypertrophy (LVH) using the Minnesota coding system. 28 Left ventricular mass (LVM) measured by magnetic resonance imaging (MRI) was available in a subset of participants. MESA cardiac MRI protocol, image analysis, interreader reproducibility, and intrareader reproducibility have been reported. 29 NT-proBNP was measured using an Elecsys electrochemiluminescence immunoassay based on a double-antibody sandwich method (Roche Diagnostics Corp, Indianapolis, IN), with intra-assay and interassay coefficients of variation of 2.7% and 3.2% at 175 pg/mL, 2.4% and 2.9% at 355 pg/mL, 1.9% and 2.6% at 1,068 pg/mL, and 1.8% and 2.3% at 4,962 pg/mL respectively. 15 Analyses were performed at the core laboratory (University of California, San Diego, CA) using a 250-KL serum sample that was previously unthawed or thawed only once. 15 Details of quality control procedures conducted at MESA coordinating centers, field centers, laboratories, and reading centers are available in the manual of operations at www.mesa-nhlbi.org.
Statistical analysis
Because of skewing, we performed natural logarithmic transformations for NT-proBNP. We grouped participants according to their early menopause status and made comparisons between them using W 2 test or Student's t test, as appropriate. We also stratified participants by the median NT-proBNP value and made comparisons across strata. Box plots were used to present the distribution of NT-proBNP values according to ethnicity in both postmenopause groups. We tested for differences in median NT-proBNP values among ethnicities in each group using Kruskal-Wallis test. Mann-Whitney U test was used to directly compare one ethnic group with another. In women of similar age and menopause status, we compared NT-proBNP levels in those with and without current smoking and diabetes.
Using multivariable linear regression, we calculated differences in log NT-proBNP values associated with early menopause and each 1-year increase in menopause age. We tested for interactions of early menopause and menopause age with ethnicity. We presented ethnicity-pooled analyses because the interaction terms of early menopause and menopause age with ethnicity were not statistically significant (P interaction = 0.47 and P interaction = 0.56, respectively). We adopted a sequential adjustment process. In model 1, we adjusted for age and BMI. In model 2, we included ethnicity. In model 3, we incorporated from previous literature potential confounders known to affect NT-proBNP (including smoking, 8, 14, 17 diabetes, 8, 17 high-density lipoprotein cholesterol, 17 glomerular filtration rate, 8, 17 systolic blood pressure, 8, 17 diastolic blood pressure, 8, 17 and use of antihypertensive medication 8, 17 ) and covariates that were associated with NT-proBNP at P G 0.10 on univariate analysis (such as educational status and interleukin-6). In model 4, we also included LVH. 17, 30, 31 Because ECG has limited sensitivity for diagnosing LVH, 32 we conducted sensitivity analysis in MRI participants in which we replaced LVH by ECG with its MRI equivalent (model 5). Women who had MRI were younger and had lower BMI. 4 In a subpopulation of MESA participants without LVH risk factors, the 95th percentile cutoff of observed/predicted LVM (1.31) was accepted as corresponding to LVH. 32 BMI is an indicator of generalized obesity but does not distinguish between muscle and fat mass. 33 Therefore, we also constructed models in which BMI was replaced with waist circumference, a stronger predictor of CVD 34 and a measure of central obesity. 35 Hyperinsulinemia has been associated with lower natriuretic peptide levels 8 ; thus, we accounted for insulin resistance in participants without diabetes by including homeostasis model assessmentYinsulin resistance in our models.
We expected older women to have a worse recollection of their menopause age; thus, we performed an analysis that excluded women who were older than 65 years. We checked for linearity by visually examining scatter plots of R-Student residuals versus predicted values. Participants missing data on a variable needed for a particular model were excluded from analyses. Two-sided P G0.05 was considered significant. Statistical analyses were performed using SAS enterprise guide version 5.1 (SAS Institute Inc, Cary, NC).
RESULTS
Of 2,275 postmenopausal women, 561 experienced early menopause. The median (25th-75th percentiles) NT-proBNP value was 79.0 (41.1-151.6) pg/mL for all participants, 83.4 (41.4-164.9) pg/mL for women with early menopause, and 78.0 (40.8-148.3) pg/mL for women without early menopause. Women with early menopause were more likely to have diabetes, greater BMI, and higher interleukin-6 levels.
Smoking was more prevalent in the early menopause group (Table 1) . Women with greater NT-proBNP levels were older, more commonly white, and likely to have hypertension. BMI was lower but interleukin-6 was greater in women with greater NT-proBNP levels. There were no differences in the use of hormone therapy across the NT-proBNP strata ( Table 1 , Supplemental Digital Content 1, http://links.lww.com/MENO/A114). In women of similar age and menopause status, the differences in NT-proBNP between smokers and nonsmokers were mostly not significant. Although the difference was not always significant, NT-proBNP generally seemed to be lower in those with diabetes than in those without diabetes among women of similar age and menopause status ( The prevalence of early menopause in white, Chinese-American, African-American, and Hispanic women was 20.9%, 13.3%, 33.6%, and 27.8%, respectively. We observed differences in the medians of NT-proBNP values among ethnicities in women with and without early menopause (P = 0.0002 and P G0.0001, respectively; Fig. A, B ). In women with early menopause, the medians of NT-proBNP values were significantly greater in whites than in African Americans (P G 0.0001) and Hispanics (P = 0.007). In those without early menopause, the medians of NT-proBNP values were significantly greater in whites than in Chinese Americans (P G 0.0001), African Americans (P G 0.0001), and Hispanics (P G 0.0001). The medians of NT-proBNP values were also significantly greater in Hispanics than in Chinese Americans (P = 0.03) and African Americans (P G 0.0001) among women without early menopause. Current cigarette smoking and hypertension were most common in African Americans in both postmenopause groups. BMI was greatest in African Americans but lowest in Chinese Americans in both postmenopause groups (Tables 3, 4 Early menopause was associated with a 10.7% increase in NT-proBNP levels, whereas each 1-year increase in menopause age was associated with a 0.7% decrease in NT-proBNP levels (model 4; Table 2 ). Similar estimates were obtained when LVH was replaced by LVM (model 5; Table 2 ). After BMI was substituted with waist circumference, our point estimates turned out to be similar because early menopause was associated with a 10.7% increase in NT-proBNP levels, whereas each 1-year increase in menopause age was associated with a 0.8% decrease in NT-proBNP levels. In women without diabetes (n = 1,987), the estimates did not differ much because early menopause was associated with a 7.3% increase in NT-proBNP levels, whereas each 1-year increase in menopause age was associated with a 0.7% decrease in NT-proBNP levels. In analysis involving women aged 65 years or younger, the patterns of association remained similar (Table 3) .
We present ethnicity-specific analysis in Table 5 , Supplemental Digital Content 5, http://links.lww.com/MENO/A118. Because of inadequate power, we cannot make definite conclusions, but the percentage differences in NT-proBNP associated with early menopause tended to be greater in African Americans. We advise caution in the interpretation of this analysis, particularly in Chinese Americans, and recommend that ethnicity-specific analysis be pursued in adequately powered studies. No significant collinearity was observed because the variance inflation factors and condition indices were fewer than five for all terms in each of our models. The percentage of missing values was less than 3% for all variables; therefore, sample sizes may have varied slightly between the models.
DISCUSSION
In our multiethnic sample of postmenopausal women without clinical CVD, early menopause was associated with greater NT-proBNP levels, whereas each 1-year increase in menopause age was associated with lower NT-proBNP levels. This association was significant after adjusting for CVD risk factors and was consistent in participants who were younger and did not have diabetes. Our findings remained consistent when LVH was assessed by MRI, which is a more sensitive measure of cardiac remodeling. 32 Our findings agree with our prior study, which showed that early menopause is associated with an increased risk of incident HF. 4 NT-proBNP has been linked to an increased risk of future HF 15 and reliably predicts HF in multiple ethnicities. 15 Early menopause was most common in African Americans and least common in Chinese Americans. We observed ethnic variations in NT-proBNP levels because greater levels were observed in white women relative to other ethnicities. However, we failed to observe significant interactions with ethnicity, suggesting that the association of menopause age and NT-proBNP may be consistent across ethnic groups. Because the associations seemed stronger when we accounted for ethnicity, we concluded that ethnicity negatively confounds the association between menopause age and NT-proBNP.
Menopause is associated with increase in fat mass, 36, 37 and the early postmenopausal women in our study accordingly had greater BMI values. Obesity (particularly BMI) is inversely associated with NT-proBNP. 17 Despite the fact that our study findings supported our hypothesis, it would seem reasonable to speculate that early menopause, which was characterized by greater BMI, could be associated with lower NT-proBNP levels. However, early menopause was significantly associated with greater NT-proBNP levels in models that included BMI; thus, we considered BMI to be a confounder of this association, which was possibly mediated by another unmeasured factor.
Hormonal changes probably contribute to changes in natriuretic peptide levels after menopause. 8 Menopause is characterized by estrogen deficiency, 9, 22 and women with early menopause would have a shorter duration of exposure to endogenous estrogens. Estrogen loss has multiple effects on the heart 38<40 and vasculature, 39, 40 one of which involves activation of the renin-angiotensin-aldosterone system (RAAS). 8, 38 Chronic activation of RAAS increases oxidative stress and reduces FIG. (A) Data points represent the median (25th-75th percentiles) for each ethnicity. Differences: whites greater than African Americans (P G 0.0001); whites greater than Hispanics (P = 0.007). The P value for detecting differences across ethnicities was calculated using Kruskal-Wallis test. Direct comparison of one ethnicity with another was performed using Mann-Whitney U test. (B) Data points represent the median (25th-75th percentiles) for each ethnicity. Differences: whites greater than Chinese Americans (P G 0.0001); whites greater than African Americans (P G 0.0001); whites greater than Hispanics (P G 0.001); Hispanics greater than Chinese Americans (P = 0.03); Hispanics greater than African Americans (P G 0.0001). The P value for detecting differences across ethnicities was calculated using Kruskal-Wallis test. Direct comparison of one ethnicity with another was performed using Mann-Whitney U test. NT-proBNP, N-terminal pro brain natriuretic peptide. nitric oxide bioavailability in estrogen-sensitive tissues, resulting in endothelial dysfunction, inflammation, and immune dysfunction. 38 These processes impair myocardial relaxation and left ventricular compliance 38 and are known pathways for the development of HF 41 and CVD. 2, 22, 42 Cardiac myocytes produce natriuretic peptides because of increased wall distension, stretching, and neurohormonal activation 7,10 that results from a reduced ventricular compliance. Natriuretic peptides have proangiogenic, antihypertrophic, and vasodilatory effects on the cardiovascular system and are also counterregulators of the RAAS and adrenergic systems. 7, 8, 13, 16 Increased NT-proBNP may indicate cardioprotective actions 8, 13, 16 against the deleterious effects of estrogen loss on the hearts of early postmenopausal women. Other sex hormones, such as testosterone and progesterone, could also contribute to cardioprotective mechanisms 43 in the hearts of postmenopausal women. Sex hormones were not measured in this study and should be explored in future studies.
The onset of menopause is associated with a greater prevalence of metabolic abnormalities 22, 42, 44 and CVD risk factors. 45, 46 In our study, women with early menopause were more likely to have diabetes, greater BMI, and indices of inflammation. Accordingly, elevated NT-proBNP levels could indicate subclinical cardiac remodeling 10 resulting from a hypoestrogenic state 40 and worse CVD profiles in women with early menopause. Lipid abnormalities in the postmenopausal period 2, 22, 45 cause increased circulating free fatty acids, and altered fatty acid metabolism in cardiomyocytes could induce cardiac lipotoxicity. 22, 41 Lipotoxicity results in apoptosis of cardiomyocytes and cardiac dysfunction, 41 which stimulate natriuretic peptide release by inducing elevated filling pressures in the heart. 10 In comparisons across similar age and postmenopause groups, our findings seemed different from those of studies that reported elevated NT-proBNP levels in smokers. 14 The tendency toward lower NT-proBNP levels in women with diabetes agrees with reports of inverse associations between plasma glucose and NT-proBNP levels. 30, 47 However, elevated NT-proBNP levels have also been reported in individuals with diabetes who had HF 48 and vascular complications. 49 Diabetes 50<53 and smoking 14, 54 cause cardiac changes through multiple mechanisms, including inflammation. Chronic inflammation promotes myocardial fibrosis and adverse remodeling, 53 which are precursors of LVH. 55 LVH is associated with elevated NT-proBNP levels 30, 31 and is a precursor to HF. 55 Collectively, we surmised that, ultimately, risk factors would adversely affect remodeling, which is associated with NT-proBNP elevation. This is the first study to demonstrate associations between menopause age and NT-proBNP. Other strengths include the availability of a multiethnic population without clinical CVD and highly standardized data collection methods. We acknowledge this study's limitations. The cross-sectional nature of our analyses limits our ability to establish causality or temporality. There is a possibility of residual confounding from unmeasured sex hormones and risk factors. Measurement error could arise because menopause status was determined by self-report, particularly in older participants. However, women have recalled their menopause age with accuracy, 56 and our associations seemed consistent in younger participants. Because of the limited number of participants in ethnic subgroups and inadequate power, we were unable to draw inferences from our ethnicity-specific analysis. Although 783 women provided information on artificial menopause resulting from oophorectomy, we had no information on chemotherapy, radiotherapy, autoimmune illness, or pelvic infections and did not perform subgroup analyses according to type of menopause (natural or artificial).
Among early postmenopausal women, 268 women experienced menopause before age 40 years and were categorized as having premature menopause. We had inadequate power for subgroup analyses according to the severity of early menopause. Genetics could affect a woman's age at menopause 21 and response to myocardial stress. 15 We did not explore the effects of genetic factors, but the role of genetics in CVD development among early postmenopausal women should be explored in future studies. NT-proBNP has marked intraindividual variability, 12 which could affect the reliability of its measurement. MESA women were aged 45 years or older at baseline; therefore, those who were yet to experience menopause were younger and would subsequently belong to the nonYearly menopause group. This could generate sampling bias, and caution must be maintained when generalizing our findings to younger populations.
CONCLUSIONS
In our multiethnic sample of postmenopausal women without clinical CVD, early menopause has been found to be associated with greater NT-proBNP levels, whereas each 1-year increase in menopause age has been found to be associated with lower NT-proBNP levels. NT-proBNP may be a useful screening test to detect high-risk women with early menopause. Even modest NT-proBNP elevations offer prognostic value before the development of clinical CVD. 57 Longitudinal studies are needed to detect disease mechanisms and to see how early menopause affects NT-proBNP levels across time.
